TRUST LITERATURE Sample Clauses

TRUST LITERATURE. Institution is not authorized to make any representations concerning shares of any Fund except those contained in the Fund's then current prospectus and statement of additional information ("SAI") and printed information issued by the Trust or by Forum as information supplemental to the prospectus. Forum will supply Institution upon its request with prospectuses, SAIs, reasonable quantities of supplemental sales literature and additional information. Institution agrees not to use other advertising or sales material relating to a Fund unless approved in writing by Forum in advance of such use. Any printed information furnished by Forum other than the then current prospectus and SAI, periodic reports and proxy solicitation materials are Forum's sole responsibility and are not the responsibility of the Trust and the Trust shall have no liability or responsibility to Institution in these respects unless expressly assumed in connection therewith. Institution shall have no responsibility with regard to the accuracy or completeness of any of the printed information furnished by Forum and shall be held harmless by Forum from and against any cost or loss arising therefrom.
Sample 1Sample 2Sample 3See All (4)
AutoNDA by SimpleDocs
TRUST LITERATURE. Parkway is not authorized to make any representations concerning shares of any Fund except those contained in the current prospectus and statement of additional information ("SAI") and printed information issued by the Trust as information supplemental to the prospectus. Parkway will supply Parkway upon its request with Prospectuses, SAIs, reasonable quantities of supplemental sales literature and additional information. Parkway agrees not to use other advertising or sales material relating to a Fund unless approved in writing by Parkway in advance of such use. Any printed information furnished by Parkway other than the then current prospectus and SAI, periodic reports and proxy solicitation materials are Parkway's sole responsibility and are not the responsibility of the Trust and the Trust shall have no liability or responsibility to Parkway in these respects unless expressly assumed in connection therewith. Parkway shall have no responsibility with regard to the accuracy or completeness of any of the printed information furnished by Parkway and shall be held harmless by Parkway from and against any cost or loss arising therefrom.
Sample 1Sample 2
TRUST LITERATURE. BDAM is not authorized to make any representations concerning shares of the Series except those contained in the appropriate then current prospectus and statement of additional information ("SAI") and printed information issued by the Trust. BDAM shall have no responsibility with regard to the accuracy or completeness of any of the printed information furnished by the Trust and shall be held harmless by the Trust from and against any cost or loss arising therefrom.
Sample 1Sample 2
TRUST LITERATURE. Institution is not authorized to make any representations concerning shares of the Series except those contained in the appropriate then current prospectus and statement of additional information ("SAI") and printed information issued by the Trust. The Trust will supply Institution upon its request with prospectuses, SAIs and additional information. Institution shall have no responsibility with regard to the accuracy or completeness of any of the printed information furnished by the Trust and shall be held harmless by the Trust from and against any cost or loss arising therefrom.
Sample 1Sample 2
TRUST LITERATURE. The Institution is not authorized to make any representations concerning Shares of any Fund or Class except those contained in the Fund's then current prospectus and statement of additional information ("SAI") and printed information issued by the Trust or by FAdS as information supplemental to the prospectus. FAdS will supply the Institution upon its request with prospectuses, SAIs, reasonable quantities of supplemental sales literature and additional information. The Institution agrees not to use other advertising or sales material relating to a Fund or Class unless approved in writing by FAdS in advance of such use. Any printed information furnished by FAdS other than the then current prospectus and SAI, periodic reports and proxy solicitation materials are FAdS's sole responsibility and are not the responsibility of the Trust, and the Trust shall have no liability or responsibility to the Institution in these respects unless expressly assumed in connection therewith. The Institution shall have no responsibility with regard to the accuracy or completeness of any of the printed information furnished by FAdS and shall be held harmless by FAdS from and against any cost or loss arising therefrom.
Sample 1Sample 2
TRUST LITERATURE. Institution is not authorized to make any representations concerning shares of any Fund except those contained in the appropriate then current prospectus and statement of additional information ("SAI") and printed information issued by the Trust as information supplemental to the prospectus. The Trust will supply Institution upon its request with prospectuses, SAIs, reasonable quantities of supplemental sales literature and additional information. Institution agrees not to use other advertising or sales material relating to any Fund unless approved in writing by the Trust in advance of such use.
Sample 1

Related to TRUST LITERATURE

  • Literature We will furnish you with copies of each Fund’s Prospectus, sales literature and other information made publicly available by the Fund, in reasonable quantities upon your request. We shall file Fund sales literature and promotional material with the NASD and SEC as required. You agree to deliver a copy of the current Prospectus to your customers in accordance with the provisions of the Securities Act of 1933. You may not publish or use any sales literature or promotional materials with respect to the Funds without our prior review and written approval.

  • Prospectuses and Marketing Materials We shall furnish you without charge reasonable quantities of offering Prospectuses (including any supplements currently in effect), current shareholder reports of the Funds, and sales materials issued by us from time to time. In the purchase of shares through us, you are entitled to rely only on the information contained in the offering Prospectus(es). You may not publish any advertisement or distribute sales literature or other written material to the public that makes reference to us or any of the Funds (except material that we furnished to you) without our prior written approval.

  • Marketing Materials (a) During the term of this Agreement, the Sub-Adviser agrees to furnish the Manager at its principal office for prior review and approval by the Manager all written and/or printed materials, including but not limited to, PowerPointÒ or slide presentations, news releases, advertisements, brochures, fact sheets and other promotional, informational or marketing materials (the “Marketing Materials”) for internal use or public dissemination, that are produced or are for use or reference by the Sub-Adviser, its affiliates or other designees, broker-dealers or the public in connection with the Series, and Sub-Adviser shall not use any such materials if the Manager reasonably objects in writing within five business days (or such other period as may be mutually agreed) after receipt thereof. Marketing Materials may be furnished to the Manager by first class or overnight mail, facsimile transmission equipment, electronic delivery or hand delivery.

  • Sales Literature Any supplemental sales literature or advertisement (including, without limitation any “broker-dealer use only” material), regardless of how labeled or described, used in addition to the Prospectus in connection with the Offering which previously has been, or hereafter is, furnished or approved by the Company (collectively, “Approved Sales Literature”), shall, to the extent required, be filed with and approved by the appropriate securities agencies and bodies, provided that the Dealer Manager will make all FINRA filings, to the extent required. Any and all Approved Sales Literature did not or will not at the time provided for use include any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein not misleading.

  • Artwork 16.01. Artist agrees that G2 is the owner of any and all artwork, LP jacket art, and promotional artistic renderings undertaken or completed within the Option Terms of this Agreement. Artist shall have the right to use artwork which has been mutually approved by G2 and Artist for the purpose of Merchandising.

  • Advertising Materials; Filed Documents (a) Advertising and sales literature with respect to any Fund prepared by the Company or its agents for use in marketing its Contracts will be submitted to that Fund or its designee for review before such material is submitted to any regulatory body for review. No such material shall be used if the Fund or its designee reasonably objects to such use in writing, transmitted by facsimile within two business days after receipt of such material.

  • Regulatory Materials (a) Alvogen shall have the sole right to control filing or submission of Regulatory Materials with the Regulatory Agencies in the Territory with respect to Product including the MAA Approval for Product and Regulatory Approvals in the Territory, subject to Section 3.2 and the oversight of and in consultation with the Executive Steering Committee, and [***]Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed. shall be responsible for managing all communications and interactions with the Regulatory Agencies in the Territory with respect to Product in the Territory. In all cases, prior to the filing of any Regulatory Materials (including the MAA for Product) for Product with the applicable Regulatory Agency, Alvogen shall provide a copy thereof to Pfenex (through the Executive Steering Committee) for its review and comment. Pfenex shall have fifteen (15) Business Days from the date it receives a copy of any Regulatory Materials with respect to the Product to provide Alvogen with comments regarding such Regulatory Materials, unless the Regulatory Agencies in the Territory or Applicable Law requires that such Regulatory Material(s) be filed on a timeline that does not reasonably permit such advanced notice, in which case Pfenex shall have as much time as is reasonably practicable to provide Alvogen with comments. Alvogen shall consider all such comments in good faith. Alvogen shall, to the extent permitted by Applicable Law, provide Pfenex with (i) reasonable advanced notice (and in no event less than fifteen (15) Business Days’ advance notice whenever feasible) of substantive meetings with any Regulatory Agency in the Territory that are either scheduled with or initiated by or on behalf of Alvogen or its Affiliates, (ii) an opportunity to have a reasonable number (but at least two (2)) representatives participate in all substantive meetings with the Regulatory Agencies in the Territory with respect to Product, and in any case keep Pfenex informed as to all material interactions with the Regulatory Agencies in the Territory with respect to Product, and (iii) a copy of any material documents, information and correspondence submitted to or received from the Regulatory Agencies in the Territory with respect to Product as soon as reasonably practicable.

  • Advertising Materials As an independent contractor, Representative has the full right to exercise his or her independent judgment in determining whether to advertise. Any advertising undertaken by Representative will be at his or her expense. However, to comply with applicable statutes, rules and regulations, Representative will submit to the Company for review all advertising or sales literature, as defined by the FINRA Rules, that Representative intends to use and obtain prior written approval of the proposed use of the literature by the Company.

  • Promotional Materials In the event that the Fund or the Adviser makes available any promotional materials related to the Securities or the transactions contemplated hereby intended for use only by registered broker-dealers and registered representatives thereof by means of an Internet web site or similar electronic means, the Adviser will install and maintain, or will cause to be installed and maintained, pre-qualification and password-protection or similar procedures which are reasonably designed to effectively prohibit access to such promotional materials by persons other than registered broker-dealers and registered representatives thereof.

  • Regulatory Filings Except as disclosed in the Registration Statement and the Prospectus, neither the Company nor any of its Subsidiaries has failed to file with the applicable Governmental Authorities (including, without limitation, the FDA, or any foreign, federal, state, provincial or local Governmental Authority performing functions similar to those performed by the FDA) any required filing, declaration, listing, registration, report or submission, except for such failures that, individually or in the aggregate, would not have a Material Adverse Effect; except as disclosed in the Registration Statement and the Prospectus, all such filings, declarations, listings, registrations, reports or submissions were in compliance with applicable laws when filed and no deficiencies have been asserted by any applicable regulatory authority with respect to any such filings, declarations, listings, registrations, reports or submissions, except for any deficiencies that, individually or in the aggregate, would not have a Material Adverse Effect. The Company has operated and currently is, in all material respects, in compliance with the United States Federal Food, Drug, and Cosmetic Act, all applicable rules and regulations of the FDA and other federal, state, local and foreign Governmental Authority exercising comparable authority. The Company has no knowledge of any studies, tests or trials not described in the Prospectus the results of which reasonably call into question in any material respect the results of the studies, tests and trials described in the Prospectus.

Time is Money Join Law Insider Premium to draft better contracts faster.